Bausch Health Acquires DURECT Corporation to Enhance Liver Disease Portfolio

Bausch Health Companies Inc. has completed its acquisition of DURECT Corporation, solidifying its position in the hepatology sector. This $63 million deal introduces larsucosterol, a promising treatment with FDA Breakthrough Therapy Designation, into Bausch Health’s pipeline. Larsucosterol targets alcohol-associated hepatitis, a condition lacking approved therapies, with a Phase 3 clinical trial in development.

The transaction includes potential milestone payments up to $350 million, contingent on achieving sales targets within the designated timeframe. Approximately 62% of DURECT’s shares were tendered, culminating in DURECT becoming a wholly owned subsidiary of Bausch Health. Trading of DURECT shares on Nasdaq has ceased in conjunction with this acquisition.